首页> 美国卫生研究院文献>NPG Open Access >Identification of a cancer stem cell-specific function for the histone deacetylases HDAC1 and HDAC7 in breast and ovarian cancer
【2h】

Identification of a cancer stem cell-specific function for the histone deacetylases HDAC1 and HDAC7 in breast and ovarian cancer

机译:鉴定乳腺癌和卵巢癌中组蛋白脱乙酰基酶HDAC1和HDAC7的癌症干细胞特异性功能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are resistant to conventional cancer therapies and play essential roles in metastasis and tumour relapse. Despite this realization and great interest in CSCs, it has been difficult to develop CSC-targeted treatments due to our limited understanding of CSC biology. Here, we present evidence that specific histone deacetylases (HDACs) play essential roles in the CSC phenotype. Utilizing a novel CSC model, we discovered that the HDACs, HDAC1 and HDAC7, are specifically over-expressed in CSCs when compared to non-stem-tumour-cells (nsTCs). Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is sufficient to augment the CSC phenotype. We also demonstrate that clinically available HDAC inhibitors (HDACi) targeting HDAC1 and HDAC7 can be used to preferentially target CSCs. These results provide actionable insights that can be rapidly translated into CSC-specific therapies.
机译:肿瘤由高度异质的细胞群组成,其中只有一小部分的干样细胞具有体内再生肿瘤的能力。这些癌症干细胞(CSC)对常规癌症疗法具有抵抗力,并且在转移和肿瘤复发中起重要作用,因此代表了重大的临床挑战。尽管认识到这一点并对CSC产生了极大的兴趣,但由于我们对CSC生物学的了解有限,因此很难开发出针对CSC的治疗方法。在这里,我们提供的证据表明,特定的组蛋白去乙酰化酶(HDACs)在CSC表型中起着至关重要的作用。利用一种新颖的CSC模型,我们发现与非干肿瘤细胞(nsTC)相比,HDAC,HDAC1和HDAC7在CSC中特别过表达。此外,我们确定HDAC1和HDAC7是维持CSC所必需的,并且HDAC7的过表达足以增强CSC表型。我们还证明,靶向HDAC1和HDAC7的临床上可用的HDAC抑制剂(HDACi)可用于优先靶向CSC。这些结果提供了可付诸实践的见解,可以迅速转化为CSC特定疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号